Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Rybrevant | amivantamab | Locally advanced or metastatic non-small cell lung cancer (NSCLC) | Pending | |||
| Ryaltris | olopatadine hydrochloride and mometasone | Seasonal allergic rhinitis | Pending | |||
| Doptelet | avatrombopag | severe thrombocytopenia associated with chronic liver disease (CLD) | Pending | |||
| Combigan Ophthalmic Solution | Brimonidine tartrate/timolol maleate | Glaucoma | List with clinical criteria and/or conditions | Complete | ||
| Reyataz | Atazanavir | HIV infection | List in a similar manner to other drugs in class | Complete | ||
| Evra | Norgelestromin/ethinyl estradiol | Contraceptive, patch | Do not list | Complete | ||
| Iressa | Gefitinib | Cancer, Lung , non-small cell | Do not list | Complete | ||
| Axert | Almotriptan | Migraine | List in a similar manner to other drugs in class | Complete | ||
| Replagal | Agalsidase alfa | Fabry Disease | Do not list | Complete | ||
| Viread | Tenofovir disoproxil fumarate | HIV infection | Do not list | Complete |
Last Updated : May 11, 2024